Skip to content

H.R. 167 · 118th Congress (2023–2025)

Patient Access to Urgent-Use Pharmacy Compounding Act of 2023

This bill relaxes certain requirements for compounding drugs that are facing shortages.

Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally, a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements.

This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for an urgent medical need not involving a specific patient if, among other requirements (1) the prescriber certifies that the prescriber is unable, despite reasonable attempts, to obtain certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug.

Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 167’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. H. Morgan Griffith (R-VA-9)
Cosponsors
12 cosponsors

1 original · 11 later

9 R · 3 D

  1. Rep. Henry Cuellar (D-TX-28)· Original · Jan 9, 2023
  2. Rep. Jeff Duncan (R-SC-3)· Later · Mar 28, 2023
  3. Rep. Diana Harshbarger (R-TN-1)· Later · May 15, 2023
  4. Rep. Gary J. Palmer (R-AL-6)· Later · Jun 5, 2023
  5. Rep. Earl L. "Buddy" Carter (R-GA-1)· Later · Jun 30, 2023
  6. Rep. Neal P. Dunn (R-FL-2)· Later · Jul 25, 2023
  7. Rep. Debbie Lesko (R-AZ-8)· Later · Aug 25, 2023
  8. Rep. Mariannette Miller-Meeks (R-IA-1)· Later · Aug 29, 2023
  9. Rep. John R. Moolenaar (R-MI-2)· Later · Sep 21, 2023
  10. Rep. Mark Pocan (D-WI-2)· Later · Dec 11, 2023
  11. Rep. Wiley Nickel (D-NC-13)· Later · Jan 25, 2024
  12. Rep. Ben Cline (R-VA-6)· Later · Mar 20, 2024
Policy area
Health
Subjects
  • Drug safety, medical device, and laboratory regulation
  • Health information and medical records
  • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Jan 9, 2023 – Jan 20, 2023
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Jan 9, 2023
  2. HouseHealthReferred Jan 20, 2023
    1. Sep 14, 2023 · Meeting

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. Patient Access to Urgent-Use Pharmacy Compounding Act of 2023

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes.

    Official title · Introduced in House